DBV Technologies (NASDAQ:DBVT) Shares Gap Down – Time to Sell?

DBV Technologies S.A. (NASDAQ:DBVT) gapped down prior to trading on Wednesday . The stock had previously closed at $23.80, but opened at $22.32. DBV Technologies shares last traded at $22.0710, with a volume of 54,863 shares traded.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on DBVT shares. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research report on Wednesday, December 17th. HC Wainwright set a $40.00 target price on shares of DBV Technologies in a research note on Thursday, December 18th. Cantor Fitzgerald set a $48.00 target price on shares of DBV Technologies in a research report on Wednesday, December 17th. Citizens Jmp lifted their price target on DBV Technologies from $21.00 to $45.00 and gave the company a “market outperform” rating in a report on Wednesday, December 17th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of DBV Technologies in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $35.38.

DBV Technologies Stock Performance

The stock has a market cap of $839.34 million, a price-to-earnings ratio of -4.04 and a beta of -0.98. The company’s 50 day simple moving average is $20.26 and its 200 day simple moving average is $14.83.

Insider Transactions at DBV Technologies

In other news, major shareholder Bpifrance Epic sold 2,076,990 shares of DBV Technologies stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $4.85, for a total transaction of $10,073,401.50. Following the transaction, the insider directly owned 8,595,472 shares in the company, valued at approximately $41,688,039.20. This trade represents a 19.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders sold 3,369,627 shares of company stock worth $15,489,908. Company insiders own 1.44% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Allworth Financial LP bought a new stake in DBV Technologies in the fourth quarter worth about $32,000. New York State Common Retirement Fund bought a new stake in DBV Technologies during the third quarter worth approximately $34,000. GAMMA Investing LLC increased its holdings in shares of DBV Technologies by 38.4% in the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after buying an additional 744 shares in the last quarter. Two Sigma Investments LP acquired a new stake in shares of DBV Technologies during the 3rd quarter valued at $167,000. Finally, Citadel Advisors LLC acquired a new position in shares of DBV Technologies in the 3rd quarter worth $220,000. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.